You just read:

Innovent Provides Update on ctDNA in Predicting Response and Resistance by Anti-PD-1 Therapy in Chinese Relapsed/Refractory Classical Hodgkin Lymphoma

News provided by

Innovent Biologics, Inc.

Jun 03, 2019, 20:00 ET